Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer

Da Tong Chu, Sang We Kim, Han Pin Kuo, Rifat Ozacar, Frantisek Salajka, S. Krishnamurthy, Danail Damyanov, Sedat Altug, William H.H. Reece, Li Wang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: In the treatment of advanced cancer, a physician's ability to accurately identify a patient's attitude towards treatment is critical. This paper describes the extent of any differences observed between patient attitudes towards chemotherapy for advanced non-small cell lung cancer (NSCLC) as assessed by patients themselves versus their physicians. Patients and methods: Patients with stage IIIB or IV NSCLC who received gemcitabine plus cisplatin or carboplatin were enrolled into this prospective observational study. Patients and their physicians completed questionnaires containing descriptions of seven patient-specific attitudes. A pre-defined algorithm was used to categorize patients into one of the three 'need' categories based on the questionnaire responses: (A) "maximum extension of survival with acceptance of high toxicity", (B) "maximum extension of survival only if coupled with normal life style", and (C) "relief of symptoms". Each patient was categorized based on his own response, as well as his physician's response. Results: A total of 1895 patients were enrolled from 19 countries across 3 continents. Data from 1884 patients were analysed. Based on patient versus physician responses, respectively, the distribution of patients was 60% versus 39% in need category A, 26% versus 33% in B, and 14% versus 29% in C. Patient self-assessed versus physician-assessed need category identification was aligned for 891 patients (47.3%): 541 (29%) in A, 218 (12%) in B, 132 (7%) in C. While there was slight agreement between the identification of 'need' categories by physicians and patients (kappa = 0.18, 95% CI: 0.15-0.21), physicians also tended to place patients further down the scale (towards C) than patients placed themselves (P < 0.001). Conclusions: Patients have varying needs from cancer chemotherapy and it may not always be correctly identified by the treating physician. Physicians may underestimate patient's desire for extended survival compared with symptom relief.

Original languageEnglish
Pages (from-to)433-443
Number of pages11
JournalLung Cancer
Volume56
Issue number3
DOIs
Publication statusPublished - Jun 1 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Observational Studies
Prospective Studies
Physicians
Drug Therapy
gemcitabine
Survival
Aptitude
Carboplatin

Keywords

  • Attitude
  • Chemotherapy
  • Gemcitabine
  • Need
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Patient attitudes towards chemotherapy as assessed by patient versus physician : A prospective observational study in advanced non-small cell lung cancer. / Chu, Da Tong; Kim, Sang We; Kuo, Han Pin; Ozacar, Rifat; Salajka, Frantisek; Krishnamurthy, S.; Damyanov, Danail; Altug, Sedat; Reece, William H.H.; Wang, Li.

In: Lung Cancer, Vol. 56, No. 3, 01.06.2007, p. 433-443.

Research output: Contribution to journalArticle

Chu, Da Tong ; Kim, Sang We ; Kuo, Han Pin ; Ozacar, Rifat ; Salajka, Frantisek ; Krishnamurthy, S. ; Damyanov, Danail ; Altug, Sedat ; Reece, William H.H. ; Wang, Li. / Patient attitudes towards chemotherapy as assessed by patient versus physician : A prospective observational study in advanced non-small cell lung cancer. In: Lung Cancer. 2007 ; Vol. 56, No. 3. pp. 433-443.
@article{50c16b21fc224250a439c9ac528fe8e9,
title = "Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer",
abstract = "Background: In the treatment of advanced cancer, a physician's ability to accurately identify a patient's attitude towards treatment is critical. This paper describes the extent of any differences observed between patient attitudes towards chemotherapy for advanced non-small cell lung cancer (NSCLC) as assessed by patients themselves versus their physicians. Patients and methods: Patients with stage IIIB or IV NSCLC who received gemcitabine plus cisplatin or carboplatin were enrolled into this prospective observational study. Patients and their physicians completed questionnaires containing descriptions of seven patient-specific attitudes. A pre-defined algorithm was used to categorize patients into one of the three 'need' categories based on the questionnaire responses: (A) {"}maximum extension of survival with acceptance of high toxicity{"}, (B) {"}maximum extension of survival only if coupled with normal life style{"}, and (C) {"}relief of symptoms{"}. Each patient was categorized based on his own response, as well as his physician's response. Results: A total of 1895 patients were enrolled from 19 countries across 3 continents. Data from 1884 patients were analysed. Based on patient versus physician responses, respectively, the distribution of patients was 60{\%} versus 39{\%} in need category A, 26{\%} versus 33{\%} in B, and 14{\%} versus 29{\%} in C. Patient self-assessed versus physician-assessed need category identification was aligned for 891 patients (47.3{\%}): 541 (29{\%}) in A, 218 (12{\%}) in B, 132 (7{\%}) in C. While there was slight agreement between the identification of 'need' categories by physicians and patients (kappa = 0.18, 95{\%} CI: 0.15-0.21), physicians also tended to place patients further down the scale (towards C) than patients placed themselves (P < 0.001). Conclusions: Patients have varying needs from cancer chemotherapy and it may not always be correctly identified by the treating physician. Physicians may underestimate patient's desire for extended survival compared with symptom relief.",
keywords = "Attitude, Chemotherapy, Gemcitabine, Need, Non-small cell lung cancer",
author = "Chu, {Da Tong} and Kim, {Sang We} and Kuo, {Han Pin} and Rifat Ozacar and Frantisek Salajka and S. Krishnamurthy and Danail Damyanov and Sedat Altug and Reece, {William H.H.} and Li Wang",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2007.01.028",
language = "English",
volume = "56",
pages = "433--443",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Patient attitudes towards chemotherapy as assessed by patient versus physician

T2 - A prospective observational study in advanced non-small cell lung cancer

AU - Chu, Da Tong

AU - Kim, Sang We

AU - Kuo, Han Pin

AU - Ozacar, Rifat

AU - Salajka, Frantisek

AU - Krishnamurthy, S.

AU - Damyanov, Danail

AU - Altug, Sedat

AU - Reece, William H.H.

AU - Wang, Li

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background: In the treatment of advanced cancer, a physician's ability to accurately identify a patient's attitude towards treatment is critical. This paper describes the extent of any differences observed between patient attitudes towards chemotherapy for advanced non-small cell lung cancer (NSCLC) as assessed by patients themselves versus their physicians. Patients and methods: Patients with stage IIIB or IV NSCLC who received gemcitabine plus cisplatin or carboplatin were enrolled into this prospective observational study. Patients and their physicians completed questionnaires containing descriptions of seven patient-specific attitudes. A pre-defined algorithm was used to categorize patients into one of the three 'need' categories based on the questionnaire responses: (A) "maximum extension of survival with acceptance of high toxicity", (B) "maximum extension of survival only if coupled with normal life style", and (C) "relief of symptoms". Each patient was categorized based on his own response, as well as his physician's response. Results: A total of 1895 patients were enrolled from 19 countries across 3 continents. Data from 1884 patients were analysed. Based on patient versus physician responses, respectively, the distribution of patients was 60% versus 39% in need category A, 26% versus 33% in B, and 14% versus 29% in C. Patient self-assessed versus physician-assessed need category identification was aligned for 891 patients (47.3%): 541 (29%) in A, 218 (12%) in B, 132 (7%) in C. While there was slight agreement between the identification of 'need' categories by physicians and patients (kappa = 0.18, 95% CI: 0.15-0.21), physicians also tended to place patients further down the scale (towards C) than patients placed themselves (P < 0.001). Conclusions: Patients have varying needs from cancer chemotherapy and it may not always be correctly identified by the treating physician. Physicians may underestimate patient's desire for extended survival compared with symptom relief.

AB - Background: In the treatment of advanced cancer, a physician's ability to accurately identify a patient's attitude towards treatment is critical. This paper describes the extent of any differences observed between patient attitudes towards chemotherapy for advanced non-small cell lung cancer (NSCLC) as assessed by patients themselves versus their physicians. Patients and methods: Patients with stage IIIB or IV NSCLC who received gemcitabine plus cisplatin or carboplatin were enrolled into this prospective observational study. Patients and their physicians completed questionnaires containing descriptions of seven patient-specific attitudes. A pre-defined algorithm was used to categorize patients into one of the three 'need' categories based on the questionnaire responses: (A) "maximum extension of survival with acceptance of high toxicity", (B) "maximum extension of survival only if coupled with normal life style", and (C) "relief of symptoms". Each patient was categorized based on his own response, as well as his physician's response. Results: A total of 1895 patients were enrolled from 19 countries across 3 continents. Data from 1884 patients were analysed. Based on patient versus physician responses, respectively, the distribution of patients was 60% versus 39% in need category A, 26% versus 33% in B, and 14% versus 29% in C. Patient self-assessed versus physician-assessed need category identification was aligned for 891 patients (47.3%): 541 (29%) in A, 218 (12%) in B, 132 (7%) in C. While there was slight agreement between the identification of 'need' categories by physicians and patients (kappa = 0.18, 95% CI: 0.15-0.21), physicians also tended to place patients further down the scale (towards C) than patients placed themselves (P < 0.001). Conclusions: Patients have varying needs from cancer chemotherapy and it may not always be correctly identified by the treating physician. Physicians may underestimate patient's desire for extended survival compared with symptom relief.

KW - Attitude

KW - Chemotherapy

KW - Gemcitabine

KW - Need

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=34247876021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247876021&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.01.028

DO - 10.1016/j.lungcan.2007.01.028

M3 - Article

C2 - 17346847

AN - SCOPUS:34247876021

VL - 56

SP - 433

EP - 443

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -